Physician

Kevin P Rosenbach, M.D.

According to 2025 Medicare claims, Kevin Rosenbach, M.D. (NPI: 1841268133) practices allergy/immunology in the Naples-Marco Island, FL market, with the plurality of this provider's patient population coming from Collier, FL. This provider's primary affiliated billing organization is KEVIN P ROSENBACH, MD PA (NPI: 1669767695; TIN: 651097669) and primary practice location at 34109-0613.

Rosenbach's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 669 traditional Medicare patients, billed 134,700 HCPCS/CPT codes, and received $7,181,377 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,477 prescription claims across 226 beneficiaries totaling $1,725,793 in drug costs, led by Gammagard Liquid (Immun Glob G(Igg)/Gly/Iga Ov50). DME data shows 4,285 claims. Open Payments data shows 67 records totaling $10,342. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $521,589 to $7,181,377. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $299,574 to $1,725,793. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	597	30,918	$521,589
2016	718	34,021	$544,927
2017	805	28,546	$415,723
2018	849	30,183	$383,062
2019	870	34,177	$453,947
2020	831	22,273	$360,207
2021	784	20,674	$353,626
2022	730	65,562	$2,782,333
2023	680	117,539	$6,049,784
2024	669	134,700	$7,181,377

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	282	1,745	$299,574
2016	361	1,938	$496,292
2017	342	1,795	$555,435
2018	294	1,660	$581,905
2019	269	1,644	$866,403
2020	260	1,597	$746,392
2021	236	1,525	$1,691,483
2022	239	1,587	$2,226,366
2023	225	1,414	$1,598,439
2024	226	1,477	$1,725,793

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	315	3,279	$2,867,637
2016	478	4,188	$4,392,569
2017	593	4,587	$5,374,208
2018	651	5,477	$6,419,749
2019	618	6,513	$7,180,970
2020	637	6,660	$9,177,636
2021	595	5,961	$9,496,028
2022	509	5,445	$10,133,434
2023	429	4,899	$9,629,758
2024	387	4,285	$8,708,875

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	336	515	$146
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	251	347	$68
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	86	1,021	$52
95165	Professional service for preparation and provision of 1 or more antigens	140	4,925	$12
95117	Professional service for multiple injections of allergen	197	2,153	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	49	1,372	$543,807
Gamunex-C	Immune Globul G/Gly/Iga Avg 46	45	1,246	$422,969
Gammaked	Immune Globul G/Gly/Iga Avg 46	13	364	$300,947
Cutaquig	Immun Glob G(Igg)-Hipp/Maltose	13	364	$168,005
Cibinqo	Abrocitinib	12	360	$69,346

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1555	Injection, immune globulin (cuvitru), 100 mg	N	58	632	$3,353,900
J1559	Injection, immune globulin (hizentra), 100 mg	N	49	497	$2,052,831
J1575	Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin	N	25	304	$1,426,734
J1554	Injection, immune globulin (asceniv), 500 mg	N	N/R	19	$562,304
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	N	N/R	90	$269,827

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	67	$10,342	ADMA BioManufacturing LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kevin P. Rosenbach, M.D.?

Tedicare shows public-source Medicare data for Kevin P. Rosenbach, M.D. (NPI 1841268133), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kevin P. Rosenbach, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Kevin P. Rosenbach, M.D.?

Kevin P. Rosenbach, M.D. is linked to KEVIN P ROSENBACH, MD PA (billing NPI 1669767695) in the available physician profile data.

Does Kevin P. Rosenbach, M.D. have Open Payments data?

Kevin P. Rosenbach, M.D. has 67 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.